1. Inicio
  2. Publicaciones
  3. The Impact of Carbapenem Resistance on Mortality in Patients With Klebsiella Pneumoniae Bloodstream Infection: An Individual Patient Data Meta-Analysis of 1952 Patients

The Impact of Carbapenem Resistance on Mortality in Patients With Klebsiella Pneumoniae Bloodstream Infection: An Individual Patient Data Meta-Analysis of 1952 Patients

Fecha de publicación: Fecha Ahead of Print:

Autores organización

Autores

  • Maraolo, AE
  • Corcione, S
  • Grossi, A
  • Signori, A
  • Alicino, C
  • Hussein, K
  • Trecarichi, EM
  • Viale, P
  • Timsit, JF
  • Veeraraghavan, B
  • Rahav, G
  • Daikos, GL
  • Vardakas, KZ
  • Roilides, E
  • Uhlemann, AC
  • Ghafur, AK
  • Pinna, SM
  • Bassetti, M
  • Kohler, PP
  • Giacobbe, DR

Grupos de investigación

Resumen

Introduction Available evidence from observational studies and meta-analyses has highlighted an increased mortality in patients with carbapenem-resistant Klebsiella pneumoniae (CRKP) bloodstream infections (BSI) compared with their carbapenem-susceptible (CSKP) counterparts, but the exact reasons for this outcome difference are still to be determined. Methods We updated the search of a previous meta-analysis through four databases up to April 2018. A two-stage individual-patient data (IPD) meta-analysis was conducted, building an adjusting model to account for age, comorbidities and activity of empirical and targeted antimicrobial therapy. The protocol was registered on PROSPERO (identifier: CRD42018104256). Results IPD data were obtained from 14 out of 28 eligible observational studies. A total of 1952 patients were investigated: 1093 in the CRKP group and 859 in the CSKP group. Patients with CRKP-BSI had a twofold risk of death compared with CSKP-infected patients [adjusted odds ratio (aOR) 2.17; 95% confidence interval (CI) 1.56-3.04; I-2 = 44.1%]. Mortality was higher in patients with CRKP BSI, in both the subgroup of absent/inactive (aOR 1.75; 95% CI 1.24-2.47; I-2 = 0) and of active initial therapy (aOR 2.66; 95% CI 1.70-4.16; I-2 = 16%) as well as in case of active targeted therapy (aOR 2.21; 95% CI 1.36-3.59; I-2 = 58%). Conclusion Resistance to carbapenem is associated with worse outcome in patients with BSI by Klebsiella pneumoniae even adjusting for comorbidities and treatment appropriateness according to in vitro activity of empirical and targeted therapy. This applies to a scenario dominated by colistin-based therapies for CRKP. Further studies are needed to compare the mortality difference between CRKP and CSKP cases in the light of new anti-CRKP antimicrobials.

Datos de la publicación

ISSN/ISSNe:
2193-8229, 2193-6382

Infectious Diseases And Therapy  Adis

Tipo:
Article
Páginas:
541-558
Enlace a otro recurso:
www.scopus.com

Citas Recibidas en Web of Science: 17

Citas Recibidas en Scopus: 30

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Active therapy; Carbapenem-resistant Klebsiella pneumoniae; Individual patient data meta-analysis; Monotherapy

Campos de estudio

Proyectos asociados

Creating a Latin America network for clinical training and support of pharmacists and hospital financial decision makers involved in ASPs

Investigador Principal: MARIA VIRGINIA VILLEGAS BOTERO

UEB-2020-585 . 2020

Caracterización Molecular de Aislamientos Resistentes a Ceftazidime Avibactam en Enterobacterales y Pseudomonas aeruginosa recolectados en cinco Países de América Latina. Molecular mechanisms leading to ceftazidime-avibactam resistance in Enterobacterales and Pseudomonas aeruginosa collected from five Latin American countries

Investigador Principal: MARIA VIRGINIA VILLEGAS BOTERO

UEB-2020-586 . 2020

Citar la publicación

Compartir la publicación